Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Inclusion Criteria: * Patients must have had histologic verification of malignancy at original diagnosis or at relapse, to include any of the following malignancies (no other histology is eligible): * Neuroblastoma- measurable * Neuroblastoma- MIBG evaluable * Rhabdomyosarcoma * Osteosarcoma * Ewing sarcoma/Peripheral PNET * Non-RMS soft tissue sarcoma * Hepatoblastoma * Malignant germ cell tumor * Wilms tumor * Acute lymphoblastic leukemia * Acute myelogenous leukemia * Rhabdoid malignancy * Disease status for solid tumor patients: * Patients must have radiographically measurable disease (with the exception of neuroblastoma) * Measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 20 mm in at least one dimension; for spiral CT, measurable disease is defined as a minimum diameter of 10 mm in at least one dimension * Note: The following do not qualify as measurable disease: * Malignant fluid collections (e.g., ascites, pleural effusions) * Bone marrow infiltration * Lesions detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography \[PET\] scans) * Elevated tumor markers in plasma or cerebrospinal fluid (CSF) * Previously irradiated lesions that have not demonstrated clear progression post radiation * Patients with neuroblastoma who do not …